Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 485Triple Negative Breast Neoplasms 28Carcinoma, Non-Small-Cell Lung 22Breast Neoplasms, Male 22Neoplasms 20Inflammatory Breast Neoplasms 20Neoplasm Metastasis 19Prostatic Neoplasms 17HER2-positive Breast Cancer 16Ovarian Neoplasms 13Lung Neoplasms 13Stomach Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Head and Neck Neoplasms 9Melanoma 8Esthesioneuroblastoma, Olfactory 8Carcinoma, Renal Cell 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Salivary Gland Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Neutropenia 6Breast Diseases 6Sarcoma 5Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Primary Breast Cancer 4Pathologic Complete Response 4Endometrial Neoplasms 4

Interventions

Trastuzumab 4pyrotinib 3Vinorelbine 2pertuzumab 1copanlisib 1Lapatinib 1Docetaxel 1Carboplatin 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Positive Breast Cancer × Docetaxel × Breast × Clear all
NCT03735966 2022-12-01

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Henan Cancer Hospital

Phase 2 Completed
75 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡